A partial or complete replacement of the bone marrow stroma by fibrous tissue. It can be a primary bone marrow lesion as part of the chronic myeloproliferative disorders (chronic idiopathic myelofibro...
Comprehensive, easy-to-understand information about this condition
How we create this content →Report Generation Failed
We couldn't automatically generate the report. This may be due to temporary service issues.
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.
Organizations with orphan designations or approved therapies for this disease
AbbVie Inc.
Other
Active Biotech AB
Other
Ajax Therapeutics, Inc.
Other
Celgene Corporation
Other
Cellenkos Inc
Other
Chengdu Zenitar Biomedical Technology Co., Ltd.
Other
Constellation Pharmaceuticals
Other
Gemin X Pharmaceuticals US, Inc.
Other
Genentech, Inc.
Other
Geron Corporation
Other
Gilead Sciences, Inc.
Other
GlaxoSmithKline LLC
Other
Incyte Corporation
Other
Kartos Therapeutics, Inc.
Other
Karyopharm Therapeutics, Inc.
Other
Lympharma LLC
Other
Merck & Co., Inc.
Other
NS Pharma, Inc.
Other
Opna Bio LLC
Other
PharmaEssentia
Other
Samus Therapeutics, Inc.
Other
Sumitomo Pharma America, Inc.
Other
Syntara Limited
Other
Telios Pharma, Inc.
Other
AI-curated news mentioning myelofibrosis
Updated Jan 23, 2026
The MPN PROGRESSion Registry is launched to track symptoms, treatments, and disease progression in individuals with myeloproliferative neoplasms (MPNs). This observational study aims to enhance understanding of conditions like Polycythemia Vera and Essential Thrombocythemia.